Parkinsonism & Related Disorders
Volume 15, Issue 1 , Pages 53-58 , January 2009

Octarepeat changes of prion protein in Parkinson's disease

  • Vinchi Wang

      Affiliations

    • Department of Neurology, Cardinal Tien Hospital, Taipei, Taiwan
    • School of Medicine, Fu-Jen Catholic University, Taipei, Taiwan
    • Wang V and Chuang TC contributed equally to this work.
    • ,
  • Tzu-Chao Chuang

      Affiliations

    • Department of Chemistry, Tamkang University, Tamsui, Taipei, Taiwan
    • Graduate Institute of Life Sciences, Tamkang University, Tamsui, Taipei, Taiwan
    • Wang V and Chuang TC contributed equally to this work.
    • ,
  • Bing-Wen Soong

      Affiliations

    • The Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
    • Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • ,
  • Din-E. Shan

      Affiliations

    • The Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
    • Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author at. Neurological Institute, Taipei Veterans General Hospital, 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. Fax: +886 2 2875 7579.
    • ,
  • Ming-Ching Kao

      Affiliations

    • Department of Biological Science and Technology, College of Life Sciences, China Medical University, Taichung, Taiwan
    • Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author at. Department of Biological Science and Technology, College of Life Sciences, China Medical University, 91 Hsueh-Shih Road, Taichung 40402, Taiwan. Tel./fax: +886 4 2205 3764.

Received 24 January 2008 ,Revised 4 March 2008 ,Accepted 5 March 2008.

References 

  1. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol. 2006;60:389–398
  2. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972–1977
  3. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci. 2001;21:8447–8455
  4. Yoo MS, Chun HS, Son JJ, DeGiorgio LA, Kim DJ, Peng C, et al. Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease. Brain Res Mol Brain Res. 2003;10:76–84
  5. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain. 2005;128:2665–2674
  6. Wang V, Chia LG, Ni DR, Cheng LJ, Ho YP, Cheng FC, et al. Effects of the combined treatment of naloxone and indomethacin on catecholamines and behavior after intranigral lipopolysaccharide injection. Neurochem Res. 2004;29:341–346
  7. Baker CA, Manuelidis L. Unique inflammatory RNA profiles of microglia in Creutzfeldt–Jakob disease. Proc Natl Acad Sci USA. 2003;100:675–679
  8. Wang V, Chuang TC, Hsu YD, Chou WY, Kao MC. Nitric oxide induces prion protein via MEK and p38 MAPK signaling. Biochem Biophys Res Commun. 2005;333:95–100
  9. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, et al. Diagnosis of new variant Creutzfeldt–Jakob disease. Ann Neurol. 2000;47:575–582
  10. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Müller U, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology. 2004;63:364–366
  11. Goldfarb LG, Petersen RB, Tabaton M, Brown P, LeBlanc AC, Montagna P, et al. Fatal familial insomnia and familial Creutzfeldt–Jakob disease: disease phenotype determined by a DNA polymorphism. Science. 1992;258:806–808
  12. Walz R, Castro RM, Velasco TR, Alexandre V, Lopes MH, Leite JP, et al. Surgical outcome in mesial temporal sclerosis correlates with prion protein gene variant. Neurology. 2003;61:1204–1210
  13. Aronoff-Spencer E, Burns CS, Avdievich NI, Gerfen GJ, Peisach J, Antholine WE, et al. Identification of the Cu2+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry. 2000;39:13760–13771
  14. Sakudo A, Lee DC, Nishimura T, Li S, Tsuji S, Nakamura T, et al. Octapeptide repeat region and N-terminal half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of superoxide dismutase. Biochem Biophys Res Commun. 2005;326:600–606
  15. Goldfarb LG, Brown P, McCombie WR, Goldgaber D, Swergold GD, Wills PR, et al. Transmissible familial Creutzfeldt–Jakob disease associated with five, seven, and eight extra octapeptide coding repeats in the PRNP gene. Proc Natl Acad Sci USA. 1991;88:10926–10930
  16. Wang KC, Wang V, Sun MC, Chiueh TI, Soong BW, Shan DE. Polymorphism distribution of prion protein codon 117, 129 and 171 in Taiwan. Eur J Epidemiol. 2007;22:257–261
  17. Scholz SW, Xiromerisiou G, Fung HC, Eerola J, Hellström O, Papadimitriou A, et al. The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations. Neurosci Lett. 2006;395:227–229
  18. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging. 2006;27:770;e1–5
  19. Gossrau G, Herting B, Möckel S, Kempe A, Koch R, Reichmann H, et al. Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. J Neural Transm. 2006;13:331–337
  20. Wadsworth JD, Asante EA, Desbruslais M, Linehan JM, Joiner S, Gowland I, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science. 2004;306:1793–1796
  21. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, et al. Predictors of survival in sporadic Creutzfeldt–Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127:2348–2359
  22. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–529
  23. Tahiri-Alaoui A, Gill AC, Disterer P, James W. Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant: implications for disease susceptibility to Creutzfeldt–Jakob disease. J Biol Chem. 2004;279:31390–31397
  24. Kashkevich K, Humeny A, Ziegler U, Groschup MH, Nicken P, Leeb T, et al. Functional relevance of DNA polymorphisms within the promoter region of the prion protein gene and their association to BSE infection. FASEB J. 2007;21:1547–1555
  25. Thanaraj TA, Clark F. Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res. 2001;29:2581–2593
  26. Wu Q, Krainer AR. U1-mediated exon definition interactions between AT-AC and GT-AG introns. Science. 1996;274:1005–1008
  27. Bocharova OV, Breydo L, Salnikov VV, Baskakov IV. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry. 2005;44:6776–6787
  28. Nadal RC, Abdelraheim SR, Brazier MW, Rigby SE, Brown DR, Viles JH. Prion protein does not redox-silence Cu2+, but is a sacrificial quencher of hydroxyl radicals. Free Radic Biol Med. 2007;42:79–89
  29. Jeong BH, Nam JH, Lee YJ, Lee KH, Jang MK, Carp RI, et al. Polymorphisms of the prion protein gene (PRNP) in a Korean population. J Hum Genet. 2004;49:319–324
  30. Brown P, Cervenáková L, Goldfarb LG, McCombie WR, Rubenstein R, Will RG, et al. Iatrogenic Creutzfeldt–Jakob disease: an example of the interplay between ancient genes and modern medicine. Neurology. 1994;44:291–293

PII: S1353-8020(08)00099-0

doi: 10.1016/j.parkreldis.2008.03.003

Parkinsonism & Related Disorders
Volume 15, Issue 1 , Pages 53-58 , January 2009

Article Tools

* Image Usage & Resolution